Technical Service Need help? Our team of experienced experts is here for you with full support.
AKA-127
7-Ethyl-10-hydroxycamptothecin
Cat. No.
AKA-127
CAS No.
86639-52-3
MF
C22H20N2O5
MW
392.4046
7-Ethyl-10-hydroxycamptothecin is a crucial intermediate of Irinotecan hydrochloride.
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Service 
86-28-85159085 
info@aktin.com
Technical Data
Description
Storage and Shipping
References
Product Name
7-Ethyl-10-hydroxycamptothecin
CAS No.
86639-52-3
MF
C22H20N2O5
MW
392.4046
Specification
98%
Description
7-Ethyl-10-hydroxycamptothecin is a crucial intermediate of Irinotecan hydrochloride. Packing: 1kg/bag; 25kg/drum or as request Availability: In Stock
Storage and Shipping
Store in a cool & dry place, keep away from strong light and heat.
References
[1]. Wallin A, et al. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential. Oncology Reports. 2008;19(6):1493-1498.
[2]. Jensen NF, et al. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations. Journal of Experimental & Clinical Cancer Research. 2016;35:56.
[3]. Kawato Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Research. 1991;51(16):4187-4191.
[4]. Jacobs AT, et al. Targeted therapy for breast cancer: An overview of drug classes and outcomes. Biochemical Pharmacology. 2022;204:115209.
[2]. Jensen NF, et al. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations. Journal of Experimental & Clinical Cancer Research. 2016;35:56.
[3]. Kawato Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Research. 1991;51(16):4187-4191.
[4]. Jacobs AT, et al. Targeted therapy for breast cancer: An overview of drug classes and outcomes. Biochemical Pharmacology. 2022;204:115209.
Disclaimer
This product is intended solely for scientific research or regulatory filing purposes. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Related Products
AKA-373
Abietic acid
CAS No.:514-10-3
MF:C20H30O2
AKA-372
Dipexion™ Fmoc-Val-Ser(psi(Me,Me)pro)-OH
CAS No.:186023-49-4
MF:C26H30N2O6
AKA-371
Dipexion™ Fmoc-Gly-Ser(psi(Me,Me)pro)-OH
CAS No.:1095952-22-9
MF:C23H24N2O6
AKA-370
Oxymatrine
CAS No.:16837-52-8
MF:C15H24N2O2
AKA-369
Matrine
CAS No.:519-02-8
MF:C15H24N2O
AKA-368
Dipexion™ Fmoc-Lys（Boc）-Thr[PSI(Me,Me)Pro]-OH
CAS No.:911838-56-7
MF:C33H43N3O8
AKA-367
Dipexion™ Fmoc-Leu-Ser[PSI(Me,Me)Pro]-OH
CAS No.:339531-50-9
MF:C27H32N2O6
AKA-366
Dipexion™ Fmoc-Ser(tBu)-Thr[PSI(Me,Me)Pro]-OH
CAS No.:1266350-99-5
MF:C29H36N2O7
AKA-365
Dipexion™ Fmoc-Glu(OtBu)-Thr[PSI(Me,Me)Pro]-OH
CAS No.:957780-56-2
MF:C31H38N2O8
AKA-364
Dipexion™ Fmoc-Lys（Boc）-Ser[PSI(Me,Me)Pro]-OH
CAS No.:957780-54-0
MF:C32H41N3O8
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.
